Canakinumab for the management of pyoderma gangrenosum: a case series of two patients and literature review
Abstract
Abstract Aims To evaluate the efficacy and adverse events of canakinumab in the treatment of pyoderma gangrenosum (PG). Methods We report two cases of refractory PG treated with canakinumab after failing multiple therapies. Results A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission. A 49-year-old male showed no improvement and suffered recurrent Pseudomonas infections, leading to treatment cessation after nine months. Conclusions We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization. Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.